GlassScriptPhysician profile
Sandhya Mehla
NPI 1215356399
$11,907.55
in general payments reported to CMS, 2019-2025
23 companies · $5,468 in 2025
The $5,468 reported for 2025 was more than what 88% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.15 · 2020: $148 · 2021: $1,441 · 2022: $2,083 · 2023: $1,536 · 2024: $1,133 · 2025: $5,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Consulting Fee: $1,525 · Education: $3.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Consulting Fee | $1,525.00 |
| Education | $3.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,291.47 | 2022-2025 | |
| Abbvie INC. | $3,594.06 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $580.35 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $451.94 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $444.52 | 2020-2021 | |
| Allergan, INC. | $298.57 | 2020-2022 | |
| Lilly USA, LLC | $257.05 | 2022-2024 | Amyvid, Emgality |
| Lundbeck LLC | $241.43 | 2019-2025 | Vyepti |
| Biogen, INC. | $127.06 | 2021-2023 | Tysabri, Vumerity |
| Scilex Pharmaceuticals INC. | $125.93 | 2024-2025 | |
| Amgen INC. | $116.14 | 2020-2023 | Aimovig |
| Impel Pharmaceuticals INC. | $82.99 | 2022 | |
| Csl Behring | $49.01 | 2021 | |
| Genzyme Corporation | $41.50 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.62 | 2024-2025 | Hyqvia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $28.46 | 2025 | Vyvgart Hytrulo |
| Upsher-Smith Laboratories LLC | $26.22 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $25.60 | 2021 | |
| Collegium Pharmaceutical, INC. | $22.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.52 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $18.98 | 2023 | Relyvrio |
| Kedrion Biopharma, INC. | $17.23 | 2024 | Gammaked, Kedrab, Koate |
| Alexion Pharmaceuticals, INC. | $13.58 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Mehla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.